Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The company is headquartered in Lund, Skane. The company went IPO on 2007-10-17. The Company’s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
Follow-Up Questions
What is the price performance of HNSBF stock?
The current price of HNSBF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Hansa Biopharma AB?
Hansa Biopharma AB belongs to Biotechnology industry and the sector is Health Care
What is Hansa Biopharma AB market cap?
Hansa Biopharma AB's current market cap is $0
Is Hansa Biopharma AB a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Hansa Biopharma AB, including 4 strong buy, 5 buy, 1 hold, 0 sell, and 4 strong sell
